Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that animal testing has proven that its DehydraTECH(TM) technology delivers cannabinoids to the bloodstream much more quickly and effectively than conventional industry formulations. According to the update, 10 male Sprague-Dawley rats were administered CBD at 25mg per kg of bodyweight in each arm of the Lexaria animal studies. Delivery of CBD into the bloodstream was monitored over a 60-minute duration and, at two minutes, 15 minutes, and 60 minutes, DehydraTECH’s LCFA formulation delivered elevated levels of CBD in blood (showing measurable and 475% and 319% greater levels, respectively) as compared to a medium chain triglyceride (“MCT”) oil formulation. Over the entire 60-minute study, the standard DehydraTECH LCFA formulation achieved an average maximum CBD blood concentration level that was 334% more than the average maximum blood concentration level of the MCT oil formulation.
To view the full press release, visit http://cnw.fm/RF6rB
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its disruptive delivery technology, which promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000
For more information please visit https://www.CannabisNewsWire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor
READ MORE: https://www.cannabisnewswire.com/cannabisnewsbreaks/cannabisnewsbreaks-lexaria-bioscience-corp-s-cse-lxx-otcqx-lxrp-dehydratech-outperforms-conventional-industry-formulations-in-animal-testing/